Palbociclib in the context of other CDK4/6 inhibitors

04/2017

MUDr. Miloš Holánek

Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

SUMMARY

Hormonal treatment in patients with disseminated, hormonal dependent breast cancer is a clearly preferred treatment alternative. It should be considered in all patients, regardless of the extent and location of the disease. Only in the case of a rapidly progressive and aggressive disease with signs of a visceral crisis is chemotherapy an option, because the onset of chemotherapy is faster than the onset of the hormone treatment. Currently, the possibilities of hormonal therapy of advanced breast cancer are changing - due to the combination of hormone therapy with cyclin-dependent kinase 4/6 inhibitors (CDK4/6), there has been a marked improvement in the effectiveness of therapy. Improvement in treatment occurred in all subgroups of patients who received CDK4/6 inhibitors. Until now, no predictor has been identified. Palbociclib, ribociclib, and abemaciclib were evaluated in clinical trials. This article summarizes the effectiveness and tolerance of these preparations.

KEY WORDS

hormonal treatment, metastatic breast cancer, aromatase inhibitors, fulvestrant, cyclin-dependent kinases 4/6 inhibitors